Guggenheim starts Keros Therapeutics with 'buy' on lung disorder drug potential

Keros Therapeutics

23/09/2024 12:10

** Guggenheim begins coverage of Keros Therapeutics  KROS.O 
with "buy" rating and PT of $96  
    ** Brokerage sees significant upside to KROS' drug,
cibotercept, being developed to treat pulmonary arterial
hypertension (PAH)
    **  PAH is a rare, progressive disorder characterized by
high blood pressure in the arteries of the lungs
    ** "We believe there is a significant commercial opportunity
in PAH for cibotercept," if it is able to show similar or better
efficacy than Merck's  MRK.N   Winrevair and avoid the bleeding
risks and other blood-related side effects associated with that
drug -brokerage
    ** KROS' hematology programs developing drug candidate
elritercept in myelodysplastic syndromes and myelofibrosis are
also "promising and commercially viable" -brokerage
    ** All 12 brokerages rate the stock "buy" or higher; their
median PT is $92
    ** Up to last close, stock up 40.3% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))